On 2 November 2016, MDxHealth - a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer - , announced the launch of a private placement through an accelerated book building of shares for an amount of approximately EUR 15 million, with the possibility to increase the size of the placement. On 3 November 2016, MDxHealth had successfully raised EUR 20.4 million. A total of 4,526,962 new shares were issued at a price of EUR 4.50 per share, implying a discount of 2.7% to the closing price prior to launch.
Despite major indices declining for 4 consecutive days and main stock indices down by 1.5% on trading day prior to launch and thanks to coordinated sales efforts, Degroof Petercam was able to generate substantial demand from long only funds and specialized investors, resulting in a meaningful oversubscription. The new shares were mostly placed with investors from the UK, Belgium and France. We are very pleased with the success of this transaction which also demonstrates our in-depth knowledge of and commitment towards healthcare companies.
MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit www.mdxhealth.com